Singapore markets closed

Cyclerion Therapeutics, Inc. (CYCN)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
3.3100+0.1900 (+6.09%)
At close: 04:00PM EDT

Cyclerion Therapeutics, Inc.

245 First Street, Riverview II
18th Floor
Cambridge, MA 02142
United States
857 327 8778

Full-time employees1

Key executives

NameTitlePayExercisedYear born
Dr. Regina Graul Ph.D.President372kN/AN/A
Ms. Rhonda M. ChickoChief Financial OfficerN/AN/A1966
Dr. Todd Milne Ph.D.Senior Vice President of External InnovationN/AN/AN/A
Ms. Jessica RennekampAssociate Director of Corporate CommunicationsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Cyclerion Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.